The phenotypic gene function analysis of OP18 described here suggests to further test a wider repertoire of OP18-directed inhibitors to therapeutically address more advanced tumor stages of bladder cancer and their conversion to less malignant stages. This evidence concerns the gene STMN1 and neoplasm.